Advertisement

Annals of Surgical Oncology

, Volume 26, Issue 1, pp 167–176 | Cite as

Adjuvant Therapy is Associated with Improved Survival in pT1N1 Gastric Cancer in a Heterogeneous Western Patient Population

  • Caitlin A. Hester
  • Mathew M. Augustine
  • John C. Mansour
  • Patricio M. Polanco
  • Adam C. Yopp
  • Herbert J. ZehIII
  • Sam C. Wang
  • Matthew R. PorembkaEmail author
Gastrointestinal Oncology
  • 89 Downloads

Abstract

Background

Two recent South Korean studies showed adjuvant therapy (AT) was not associated with improved survival in pT1N1 gastric adenocarcinoma (GAC). We established the prognostic utility of lymph node status, determined the pattern of use of AT, and compared survival stratified by type of AT in pT1N1 GAC in a Western patient population.

Methods

We identified patients with pT1N0 and pT1N1 GAC using the National Cancer Database from 2004 to 2012. Clinicopathologic variables, treatment regimens, and overall survival (OS) were compared.

Results

We compared 4516 (86.6%) pT1N0 to 696 (13.4%) pT1N1 patients. pT1N1 tumors were larger (median size 2.5 vs. 1.8 cm, p < 0.001), more often poorly differentiated (56.2% vs. 39.6%, p < 0.001), and had higher median retrieved lymph nodes (RLN) (14 vs. 12, p < 0.001) compared with pT1N0. pT1N1 was associated with worse median overall survival (OS) (6.9 vs. 9.9 years for pT1N0, p < 0.001). pN1 was independently associated with worse OS (hazard ratio [HR] 2.17, 95% confidence interval [CI] 1.84–2.56). Increased RLN was associated with improved OS (HR 0.73, 95% CI 0.65–0.83). Among pT1N1 patients, 330 (47.4%) had observation (OBS), 77 (11.1%) received adjuvant chemotherapy (ACT), 68 (9.8%) received adjuvant radiation therapy (ART), and 221 (31.8%) received adjuvant chemoradiation therapy (ACRT). ACT and ACRT were independently associated with improved OS (HR 0.37, 95% CI 0.22–0.65 and HR 0.40, 95% CI 0.28–0.57).

Conclusions

pN1 was associated with worse survival and RLN ≥ 15 was associated with improved survival in pT1 GAC. ACT and ACRT were independently associated with improved survival in pT1N1 gastric cancer suggesting a valuable role in Western patients.

Notes

Acknowledgments

Sam C. Wang is supported by the University of Texas Southwestern Medical Center Disease-Oriented Clinical Scholarship. Matthew R. Porembka is a Dedman Family Scholar in Clinical Care.

Disclosures

No financial or commercial disclosures.

Supplementary material

10434_2018_6995_MOESM1_ESM.docx (46 kb)
Supplementary material 1 (DOCX 46 kb)

References

  1. 1.
    Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–30.CrossRefGoogle Scholar
  2. 2.
    Al-Batran SE, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016;17:1697–708.CrossRefGoogle Scholar
  3. 3.
    National Comprehnsive Cancer Network. National Comprehensive Cancer Network (NCCN) Guidelines (Version 1.2018 GC).Google Scholar
  4. 4.
    Kim SM, An JY, Lee J, Sohn TS, Kim S. Adjuvant Chemotherapy Versus Chemoradiotherapy Versus Surgery Alone for Early Gastric Cancer with One or Two Lymph Node Metastasis. Ann Surg Oncol. 2018;25:1616–24.CrossRefGoogle Scholar
  5. 5.
    Shin HB, An JY, Lee SH, et al. Is adjuvant chemotherapy necessary in pT1N1 gastric cancer? BMC Cancer. 2017;17:287.CrossRefGoogle Scholar
  6. 6.
    NCCN clinical practice guidelines in oncology, gastric cancer. 2017. https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. Accessed 12 Oct 2017.
  7. 7.
    Association JGC. Japanese Gastric Cancer Treatment Guidelines 2010 (Version 3). Gastric Cancer. 116:5592–8.Google Scholar
  8. 8.
    Merchant SJ, Li L, Kim J. Racial and ethnic disparities in gastric cancer outcomes: more important than surgical technique? World J Gastroenterol. 2014;20:11546–51.CrossRefGoogle Scholar
  9. 9.
    Kim J, Sun CL, Mailey B, et al. Race and ethnicity correlate with survival in patients with gastric adenocarcinoma. Ann Oncol. 2010;21:152–60.CrossRefGoogle Scholar
  10. 10.
    Nelson R, Ko EB, Arrington A, et al. Race and correlations between lymph node number and survival for patients with gastric cancer. J Gastrointest Surg. 2013;17:471-81.CrossRefGoogle Scholar
  11. 11.
    American College of Surgeons: National cancer database. 1996–2017. Available at: https://www.facs.org/quality-programs/cancer/ncdb. Accessed 7 Sept. 2017.
  12. 12.
    Wu CW, Hsieh MC, Lo SS, et al. Prognostic indicators for survival after curative resection for patients with carcinoma of the stomach. Dig Dis Sci 1997;42:1265–9.CrossRefGoogle Scholar
  13. 13.
    Zhou Y, Yu F, Wu L, Ye F, Zhang L, Li Y. Survival after gastrectomy in node-negative gastric cancer: a review and meta-analysis of prognostic factors. Med Sci Monit. 2015;21:1911–9.CrossRefGoogle Scholar
  14. 14.
    Gotoda T, Yanagisawa A, Sasako M, et al. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer. 2000;3:219–25.CrossRefGoogle Scholar
  15. 15.
    Roviello F, Rossi S, Marrelli D, et al. Number of lymph node metastases and its prognostic significance in early gastric cancer: a multicenter Italian study. J Surg Oncol. 2006;94:275–80; discussion 4.CrossRefGoogle Scholar
  16. 16.
    Marrelli D, Pedrazzani C, Corso G, et al. Different pathological features and prognosis in gastric cancer patients coming from high-risk and low-risk areas of Italy. Ann Surg. 2009;250:43–50.CrossRefGoogle Scholar
  17. 17.
    Degiuli M, De Manzoni G, Di Leo A, et al. Gastric cancer: current status of lymph node dissection. World J Gastroenterol. 2016;22:2875–93.CrossRefGoogle Scholar
  18. 18.
    Li F, Zhang R, Liang H, Liu H, Quan J. The pattern and risk factors of recurrence of proximal gastric cancer after curative resection. J Surg Oncol. 2013;107:130–5.CrossRefGoogle Scholar
  19. 19.
    Kang WM, Meng QB, Yu JC, Ma ZQ, Li ZT. Factors associated with early recurrence after curative surgery for gastric cancer. World J Gastroenterol. 2015;21:5934–40.CrossRefGoogle Scholar
  20. 20.
    Kong SH, Lee HJ, Ahn HS, et al. Stage migration effect on survival in gastric cancer surgery with extended lymphadenectomy: the reappraisal of positive lymph node ratio as a proper N-staging. Ann Surg. 2012;255:50–8.CrossRefGoogle Scholar
  21. 21.
    Kim YI. Is retrieval of at least 15 lymph nodes sufficient recommendation in early gastric cancer? Ann Surg Treat Res. 2014;87:180-4.CrossRefGoogle Scholar
  22. 22.
    Mokdad AH, Dwyer-Lindgren L, Fitzmaurice C, et al. Trends and patterns of disparities in cancer mortality among US counties, 1980-2014. JAMA. 2017;317:388–406.CrossRefGoogle Scholar
  23. 23.
    Nassour I, Fullington H, Hynan LS, et al. The yield of staging laparoscopy in gastric cancer is affected by racial and ethnic differences in disease presentation. Ann Surg Oncol. 2017;24:1787–94.CrossRefGoogle Scholar
  24. 24.
    Choi IJ, Lee JH, Kim YI, et al. Long-term outcome comparison of endoscopic resection and surgery in early gastric cancer meeting the absolute indication for endoscopic resection. Gastrointest Endosc. 2015;81:333-41 e1.CrossRefGoogle Scholar
  25. 25.
    Sekiguchi M, Suzuki H, Oda I, et al. Favorable long-term outcomes of endoscopic submucosal dissection for locally recurrent early gastric cancer after endoscopic resection. Endoscopy. 2013;45:708–13.CrossRefGoogle Scholar
  26. 26.
    Kim MY, Cho JH, Cho JY. Ever-changing endoscopic treatment for early gastric cancer: yesterday-today-tomorrow. World J Gastroenterol. 2014;20:13273–83.CrossRefGoogle Scholar
  27. 27.
    Kitagawa Y, Fujii H, Kumai K, et al. (2005) Recent advances in sentinel node navigation for gastric cancer: a paradigm shift of surgical management. J Surg Oncol. 90:147–51.CrossRefGoogle Scholar
  28. 28.
    Kelder W, Nimura H, Takahashi N, Mitsumori N, van Dam GM, Yanaga K. Sentinel node mapping with indocyanine green (ICG) and infrared ray detection in early gastric cancer: an accurate method that enables a limited lymphadenectomy. Eur J Surg Oncol. 2010;36:552–8.CrossRefGoogle Scholar
  29. 29.
    Sanjeevaiah A, Cheedella N, Hester C, Porembka MR. Gastric cancer: recent molecular classification advances, racial disparity, and management implications. J Oncol Pract. 2018;14:217–24.CrossRefGoogle Scholar
  30. 30.
    Rajabi B, Corral JC, Hakim N, Mulla ZD. Descriptive epidemiology of gastric adenocarcinoma in the state of Texas by ethnicity: Hispanic versus white non-Hispanic. Gastric Cancer. 2012;15:405–13.CrossRefGoogle Scholar
  31. 31.
    Wu X, Chen VW, Andrews PA, Ruiz B, Correa P. Incidence of esophageal and gastric cancers among Hispanics, non-Hispanic whites and non-Hispanic blacks in the United States: subsite and histology differences. Cancer Causes Control. 2007;18:585–93.CrossRefGoogle Scholar
  32. 32.
    Wu X, Chen VW, Ruiz B, Andrews P, Su LJ, Correa P. Incidence of esophageal and gastric carcinomas among American Asians/Pacific Islanders, whites, and blacks: subsite and histology differences. Cancer. 2006;106:683–92.CrossRefGoogle Scholar
  33. 33.
    Howard JH, Hiles JM, Leung AM, Stern SL, Bilchik AJ. Race influences stage-specific survival in gastric cancer. Am Surg. 2015;81:259–67.Google Scholar
  34. 34.
    Fukuhara S, Yabe M, Montgomery MM, Itagaki S, Brower ST, Karpeh MS, Jr. Race/Ethnicity is predictive of lymph node status in patients with early gastric cancer. J Gastrointest Surg. 2014;18:1744–51.CrossRefGoogle Scholar
  35. 35.
    Chen Y, Haveman JW, Apostolou C, Chang DK, Merrett ND. Asian gastric cancer patients show superior survival: the experiences of a single Australian center. Gastric Cancer. 2015;18:256–61.CrossRefGoogle Scholar
  36. 36.
    Lee J, Lim DH, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30:268–73.CrossRefGoogle Scholar
  37. 37.
    Winchester DP, Stewart AK, Phillips JL, Ward EE. The national cancer data base: past, present, and future. Ann Surg Oncol. 2010;17:4–7.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Caitlin A. Hester
    • 1
  • Mathew M. Augustine
    • 1
    • 2
  • John C. Mansour
    • 1
  • Patricio M. Polanco
    • 1
  • Adam C. Yopp
    • 1
  • Herbert J. ZehIII
    • 1
  • Sam C. Wang
    • 1
  • Matthew R. Porembka
    • 1
    Email author
  1. 1.Division of Surgical Oncology, Department of SurgeryUniversity of Texas Southwestern Medical CenterDallasUSA
  2. 2.Department of Veterans Affairs North Texas Health Care SystemDallasUSA

Personalised recommendations